Pravastatin is useful for prevention of recurrent severe placenta-mediated complications – a pilot study
| Autor: | Jessica Asher-Landsberg, Yariv Yogev, Chagit Kliger, Michael J. Kupferminc, Eli Rimon, Avital Skornick-Rapaport, Ronni Gamzu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Placenta Pilot Projects macromolecular substances Preeclampsia 03 medical and health sciences 0302 clinical medicine Pre-Eclampsia Pregnancy medicine Humans 030212 general & internal medicine Abruptio Placentae reproductive and urinary physiology Pravastatin Retrospective Studies Fetus Fetal Growth Retardation 030219 obstetrics & reproductive medicine Aspirin Placental abruption Obstetrics business.industry musculoskeletal neural and ocular physiology Obstetrics and Gynecology Heparin Low-Molecular-Weight Stillbirth medicine.disease medicine.anatomical_structure nervous system embryonic structures Pediatrics Perinatology and Child Health Female business medicine.drug |
| Zdroj: | The Journal of Maternal-Fetal & Neonatal Medicine. 35:8055-8061 |
| ISSN: | 1476-4954 1476-7058 |
| Popis: | Preeclampsia with severe features and other severe placenta-mediated complications may be life threatening to mother and fetus, especially when they are recurrent. Recurrence of pregnancy complications is common, however, when combined treatment with low molecular weight heparin and low dose aspirin fails, there are not any proven therapeutic options for prevention of recurrence of obstetrical complications.We aimed to determine the impact of adding pravastatin to low molecular weight heparin and low dose aspirin for improving pregnancy outcome in women with severe recurrent placenta-mediated complications.A retrospective study of 32 women with severe recurrent placenta-mediated complications (preeclampsia with severe features, placental abruption, severe intrauterine growth retardation or intra uterine fetal death) in spite of treatment with low molecular weight heparin and low dose aspirin in previous pregnancy. All women were treated in the index pregnancy with 20 mg pravastatin starting at 12 weeks, with low molecular weight heparin and low dose aspirin. Antiphospholipid syndrome was evident for 10 of the 32 women.In the index pregnancy, only one woman had recurrence of severe placenta-mediated complications. Gestational age at delivery in the index pregnancy compared to previous pregnancy when women were treated with low molecular weight heparin and low dose aspirin was 36.5 ± 1.7 vs. 32 ± 3.6 weeks, and mean birth weight 2691 ± 462 vs. 1436 ± 559 grams, compared to previous pregnancy when women were treated with low molecular weight heparin and low dose aspirin (Additive treatment with pravastatin to low molecular weight heparin and low dose aspirin may be a promising option in cases of previous severe recurrent placenta-mediated complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|